Retina

Katja Hatz MD discusses the promising one-year results achieved with Oraya Therapy at her centre in Switzerland.

Mahdy Ranjbar, MD, discusses using Oraya Therapy in practice in Germany.

Frank Zimmermann MD discusses Oraya therapy in Neovascular AMD, its mechanisms and synergy with Anti-VEGF

UK Eye Doctor Christopher Brand speaks at the EURETINA conference in September 2015

Results from the INTREPID study show that, in eyes with neovascular AMD, a single treatment of stereotactic radiotherapy with the Oraya Therapy can significantly reduce intravitreal injections over two years of follow-up while maintaining vision. Supplement includes authors Tim Jackson, PhD, FRCOphth; Frank Zimmerman, MD; Mahdy Ranjbar, MD; Katja Hatz, MD; and Christopher Brand, FRCOphth.

Highlights from Bayer’s Satellite Symposium ‘Eylea®(aflibercept solution for injection) for Visual Impairment due to Diabetic Macular Edema: Every Letter Matters, Every Day,’ held on September 18, 2015, at the 15th EURETINA Congress, Nice, France

How the OS4® and HDC Control Take Your Vitreoretinal Surgery to the Next Level

Photoreceptors – and the retina in general – are highly metabolically active. But their maxed-out mitochondria can’t give much more. And when even small metabolic imbalances arise…

The unveiling of SPECTRALIS® OCT angiography* is one of the highlights for Heidelberg Engineering in 2016. Its Managing Director Dr. Kester Nahen explains the distinctive features and new possibilities of this technology.

More than 400 participants from 49 countries accepted an invitation from the Heidelberg Engineering Academy to the 13th International SPECTRALIS Symposium (ISS) in Valencia, Spain, held on October 16 and 17, 2015. This success was certainly partly due to the attractive venue, but above all, it can be attributed to the high-level international faculty, the interesting scientific program, and the constructive discussions generated.